Gastroenterology Therapies Referring Physician Orders Rev. 11/2024ss

Contact us with questions at: 804-442-3558 or email: referrals@theinfusionsolution.com

Please fax completed referral form & all required documents to 804-554-5848



		PATIENT DI	EMOGRAPI	HICS				
Patient Name:			DOB: Phone:					
Address:								
Allergies:			□ NKDA	Weight:	□ lbs □ kg ⊢	leight:	□ in □ cm	
<u> </u>	INSURANCE INFOR	·				J	_	
DIAGNOSIS*								
*ICD 10 Code ☐ Crohn's Disea	se (K50.00-K50.919), ic			er.		ICD10		
	itis (K51.00-K51.919), ic			<u></u>		, 10210 _		
INFUSION ORDERS								
MEDICATION	MEDICATION DOSE DIRECTIONS/DURATION							
Entyvio® (vedolizumab)	300mg				inutes at Weeks 0, 2, 6	then every 8 we	eks x 1 vear	
, . (,				☐ MAINTENANCE: Infuse IV over 30 minutes every 8 weeks x 1 year				
Infliximab and biosimilars:	□ mg (5 mg/kg)	☐ INITIAL: I	nfuse IV over 2 h	ours at Weeks 0, 2, 6,	then every 8 wee	eks x 1 year	
☐ Remicade®	□ mg (′			 □ MAINTENANCE: Infuse IV over 2 hours every 8 weeks x 1 year □ MAINTENANCE: Infuse IV over 2 hours every weeks x 1 year 				
Renflexis®	mg (mg/kg)				weeks x 1 y	/ear	
Omvoh™ (mirikizumab) Skyrizi® (risankizumab)	· · · · · · · · · · · · · · · · · · ·		☐ Infuse IV over 30 minutes every 4 weeks x 3 doses ☐ Infuse 600mg IV over 1 hour every 4 weeks x 3 doses					
□ 1200mg (for UC)			☐ Infuse 1200mg IV over 1 hour every 4 weeks x 3 doses					
Stelara® (ustekinumab) INITIAL IV Dose:			☐ Infuse IV over 1 hour x 1 dose					
,	mg							
	☐ 55kg to 85kg ☐ >85kg – 520	-						
Tremfya® (guselkumab)	200mg	☐ Infuse IV over 1 hour every 4 weeks x 3 doses						
Tysabri® (natalizumab) 300mg			☐ Infuse IV over 1 hour every 4 weeks x months					
☐ Patient enrolled in TOUCH			*Observe patient for 1 hour after completion of infusion.*					
Prescribing Program ☐ If no hypersensitivity reaction observed with first 12 infusions, then post infusion observations as directed by MD.							then post-	
**For drug doses that are calculated based	on patient weight, a new ord	er will be requested for			directed by MD.			
Is the patient currently receiving the				☐ YES				
If yes, Facility Name: Date of last treatment: Date of next treatment:								
OTHER ORDERS								
LAB ORDERS: Labs to be dr	awn by: Infusion	Center [☐ Referring Ph	nysician				
☐ No labs ordered at this time			E 500	_				
□ CBC q □ CMP	'q ⊔ C	KP q	LI ESR q_	Ц	LFIS q	. 🗆 Other:		
PRE-MEDICATION ORDERS: ☐ No premeds ordered at this	timo		□ Dinh	onbydramina 2	5ma P∩			
☐ No premeds ordered at this time ☐ Acetaminophen 650mg PO			☐ Diphenhydramine 25mg PO ☐ Methylprednisolone 40mg IVP -OR- ☐ Hydrocortisone 100mg IV					
□ Other:								
	REF	ERRING PH	YSICIAN IN	FORMATION				
Physician Signature:					Date:			
Physician Name:								
Address:								
			Fax #:					
Email Where Follow Up Documental								
				MENTATION				
Please attach medical reco	oras: initiai H&P, cui	rent MD progre	ess notes, m	edication list, a	ind labs/test result	s to support o	ilagnosis.	
TB Screening for Cimzia, Entyvio, i	nfliximab biosimilars, Om	voh, Skyrizi, Stelai	ra and Tremfya (submit results from	n within 12 months to sta	art and annually	to continue therapy)	
 Annual TB screening to 	,	fusion Center		ng Physician				
Hepatitis B Screening for Cimzia arJC virus (JCV) antibody testing for				o continue therapy	'n			
Continuation labs to be		fusion Center		ng Physician	,			
Prior Failed Therapies (including	ng DMARDs, immun	osuppressants	, and biologic	cs)				
		<u> </u>	Re	Reason for D/C:				
				Reason for D/C:				
					Reason for D/C:			
Medication Failed:	1)a	es of Treatment	•	R	eason for D/C:			